New radiation cocktail aims to stop prostate cancer before it spreads

NCT ID NCT06881823

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study was designed to test two experimental drugs, AAA602 and AAA802, which deliver radiation directly to prostate cancer cells. Men with high-risk localized prostate cancer would have received these drugs before surgery to remove the prostate and nearby lymph nodes. The goal was to see if this approach could lower the chance of cancer returning. However, the trial was withdrawn before any participants were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AAA602 (Lutetium-177) and AAA802 (Actinium-225) - targeted radiation drugs that seek out prostate cancer cells

What this could lead to

If successful, this approach could reduce the risk of prostate cancer returning after surgery by destroying cancer cells before the operation.

What could go wrong

This trial was withdrawn before enrolling any participants, so no results are available. The drugs may cause side effects from radiation, and it is unknown if they will improve outcomes compared to standard treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.